|
1
|
Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama
T, Kimura T, Yoshino K, Fujita M, Kimura T and Enomoto T:
Biomarkers for screening, diagnosis, and monitoring of ovarian
cancer. Cancer Epidemiol Biomarkers Prev. 21:1902–1912. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berek JS, Crum C and Friedlander M: Cancer
of the ovary, fallopian tube, and peritoneum. Int J Gynaecol
Obstet. 119(Suppl 2): S118–S129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Husseinzadeh N: Status of tumor markers in
epithelial ovarian cancer has there been any progress? A review
Gynecol Oncol. 120:152–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosen DG, Wang L, Atkinson JN, Yu Y, Lu
KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr:
Potential markers that complement expression of CA125 in epithelial
ovarian cancer. Gynecol Oncol. 99:267–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bast RC Jr, Badgwell D, Lu Z, et al: New
tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl 3):
274–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Medeiros LR, Rosa DD, da Rosa MI, et al:
Accuracy of CA 125 in the diagnosis of ovarian tumors: a
quantitative systematic review. Eur J Obstet Gynecol Reprod Biol.
142:99–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kirchhoff C: Molecular characterization of
epididymal proteins. Rev Reprod. 3:86–95. 1998. View Article : Google Scholar
|
|
8
|
Galgano MT, Hampton GM and Frierson HF Jr:
Comprehensive analysis of HE4 expression in normal and malignant
human tissues. Mod Pathol. 19:847–853. 2006.PubMed/NCBI
|
|
9
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
10
|
Li J, Dowdy S, Tipton T, Podratz K, Lu WG,
Xie X and Jiang SW: HE4 as a biomarker for ovarian and endometrial
cancer management. Expert Rev Mol Diagn. 9:555–566. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anastasi E, Marchei GG, Viggiani V, et al:
HE4: a new potential early biomarker for the recurrence of ovarian
cancer. Tumour Biol. 31:113–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moore RG and Maclaughlan S: Current
clinical use of biomarkers for epithelial ovarian cancer. Curr Opin
Oncol. 22:492–497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tempany CM, Zou KH, Silverman SG, Brown
DL, Kurtz AB and McNeil BJ: Staging of advanced ovarian cancer:
comparison of imaging modalities - report from the Radiological
Diagnostic Oncology Group. Radiology. 215:761–767. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gronlund B, Høgdall C, Hilden J, Engelholm
SA, Høgdall EV and Hansen HH: Should CA-125 response criteria be
preferred to Response Evaluation Criteria In Solid Tumors (RECIST)
for prognostication during second-line chemotherapy of ovarian
carcinoma? J Clin Oncol. 22:4051–4058. 2004. View Article : Google Scholar
|
|
15
|
Gu P, Pan LL, Wu SQ, et al: CA 125, PET
alone, PET-CT, CT and MRI in diagnosing recurrent ovarian
carcinoma: a systematic review and meta-analysis. Eur J Radiol.
71:164–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Togashi K: Ovarian cancer: the clinical
role of US, CT, and MRI. Eur Radiol. 13(Suppl 4): L87–L104. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goonewardene TI, Hall MR and Rustin GJ:
Management of asymptomatic patients on follow-up for ovarian cancer
with rising CA-125 concentrations. Lancet Oncol. 8:813–821. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aebi S and Castiglione M; ESMO Guidelines
Working Group. Newly and relapsed epithelial ovarian carcinoma:
ESMO clinical recommendations for diagnosis, treatment and
follow-up. Ann Oncol. 20(Suppl 4): 21–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sturgeon CM, Duffy MJ, Stenman U-H, et al:
National Academy of Clinical Biochemistry laboratory medicine
practice guidelines for use of tumor markers in testicular,
prostate, colorectal, breast, and ovarian cancers. Clin Chem.
54:e11–e79. 2008. View Article : Google Scholar
|
|
20
|
Bast RC Jr: Status of tumor markers in
ovarian cancer screening. J Clin Oncol. 21(Suppl 10): s200–s205.
2003. View Article : Google Scholar
|
|
21
|
Moore RG, Jaube-Raughley M, Brown AK, et
al: Comparison of a novel multiple marker assay vs. the Risk of
Malignancy Index for the prediction of epithelial ovarian cancer in
patients with a pelvic mass. Am J Obstet Gynecol. 203:e1–e6. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schummer M, Drescher C, Forrest R, Gough
S, Thorpe J, Hellström I, Hellström KE and Urban N: Evaluation of
ovarian cancer remission markers HE4, MMP7 and Mesothelin by
comparison to the established marker CA125. Gynecol Oncol.
125:65–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hori SS and Gambhir SS: Mathematical model
identifies blood biomarker-based early cancer detection strategies
and limitations. Sci Transl Med. 3:109ra1162011.PubMed/NCBI
|
|
24
|
Häfner N, Nicolaus K, Weiss S, Frey M,
Diebolder H, Rengsberger M, Dürst M and Runnebaum IB:
p53-autoantibody may be more sensitive than CA-125 in monitoring
microscopic and macroscopic residual disease after primary therapy
for epithelial ovarian cancer. J Cancer Res Clin Oncol.
139:1207–1210. 2013.PubMed/NCBI
|
|
25
|
Rustin GJ: Follow-up with CA125 after
primary therapy of advanced ovarian cancer has major implications
for treatment outcome and trial performances and should not be
routinely performed. Ann Oncol. 22(Suppl 8): viii45–iii48. 2011.
View Article : Google Scholar
|
|
26
|
Rustin GJ, van der Burg ME, Griffin CL, et
al: Early versus delayed treatment of relapsed ovarian cancer (MRC
OV05/EORTC 55955): a randomised trial. Lancet. 376:1155–1163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Forstner R, Sala E, Kinkel K and Spencer
JA; European Society of Urogenital Radiology. ESUR guidelines:
ovarian cancer staging and follow-up. Eur Radiol. 20:2773–2780.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coakley FV, Choi PH, Gougoutas CA, Pothuri
B, Venkatraman E, Chi D, Bergman A and Hricak H: Peritoneal
metastases: detection with spiral CT in patients with ovarian
cancer. Radiology. 223:495–499. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sala E, Kataoka M, Pandit-Taskar N, Ishill
N, Mironov S, Moskowitz CS, Mironov O, Collins MA, Chi DS, Larson S
and Hricak H: Recurrent ovarian cancer: use of contrast-enhanced CT
and PET/CT to accurately localize tumor recurrence and to predict
patients’ survival. Radiology. 257:125–134. 2010.PubMed/NCBI
|
|
30
|
Diniz Bizzo SM, Meira DD, Lima JM, da
Mororó JS, Casali-da-Rocha JC and Ornellas MH: Peritoneal VEGF
burden as a predictor of cytoreductive surgery outcome in women
with epithelial ovarian cancer. Int J Gynaecol Obstet. 109:113–117.
2010.PubMed/NCBI
|
|
31
|
Kang S: The role of neoadjuvant
chemotherapy in ovarian cancer patients with extensive tumor
burden. J Gynecol Oncol. 22:299–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Midulla C, Manganaro L, Longo F, Viggiani
V, Frati L, Granato T and Anastasi E: HE4 combined with MDCT
imaging is a good marker in the evaluation of disease extension in
advanced epithelial ovarian carcinoma. Tumour Biol. 33:1291–1298.
2012. View Article : Google Scholar : PubMed/NCBI
|
